BPH - Benign Prostatic Enlargement
Symptomatic Benign Prostate Hyperplasia May Increase the Risk of Kidney Stones.
- Details
Benign prostatic hyperplasia (BPH) and kidney stones are among the most common benign urologic conditions in males. A key risk factor for kidney stones is low fluid intake. Males with BPH frequently restrict fluid intake to manage lower urinary tract symptoms, potentially increasing their stone risk.
5 Alpha Reductase Inhibitors (5ARIs) Monotherapy and Combinations: Current Role in Benign Prostatic Hyperplasia (BPH) Management.
- Details
Background and Objectives: Benign prostatic hyperplasia (BPH) is a progressive, androgen-dependent condition driven by dihydrotestosterone (DHT). 5α-reductase inhibitors (5-ARIs), including finasteride and dutasteride, target this pathway and provide disease-modifying effects.
Targeting fibrosis in the treatment of lower urinary tract dysfunction.
- Details
Benign prostatic hyperplasia (BPH) is a widely prevalent age-associated disease that is the main contributor to lower urinary tract dysfunction (LUTD) in aging men. Although prostate fibrosis has been recognized as a contributor to BPH pathophysiology, there are not any clinically available therapeutics that target this aspect of disease progression.
Comparison of Urodynamic Outcomes of Surgery Using the Photoselective Vaporization 180 W XPS System and Transurethral Resection of the Prostate: A Propensity Score-Matched Analysis in Real-World Clinical Practice.
- Details
No previous studies have directly compared pre- and postoperative pressure flow study (PFS) outcomes between transurethral resection of the prostate (TURP) and photoselective vaporization of the prostate using the GreenLight XPS laser system (PVP-XPS).
Comparison of Robotic vs Laser Enucleation of the Prostate for Treatment of Benign Prostatic Hyperplasia.
- Details
To compare robotic transabdominal enucleation of the prostate (RTEP) and laser enucleation of the prostate (LEP) concerning perioperative and functional outcomes for the treatment of benign prostatic hyperplasia (BPH).
Antifibrotic therapy for Lower Urinary Tract Symptoms secondary to Benign Prostatic Hyperplasia.
- Details
Lower Urinary Tract Symptoms secondary to Benign Prostatic Hyperplasia (LUTS/BPH) are a ubiquitous condition estimated to affect over 50% of men over the age of 50 years. Various treatment options exist for men presenting with LUTS/BPH, including lifestyle and behavioral modification and medical or surgical treatment.
Transperineal Laser Ablation of Symptomatic Benign Prostatic Hyperplasia With Median-Lobe Enlargement: A Single-Center Experience.
- Details
Benign prostatic hyperplasia (BPH) with median-lobe enlargement (MLE) is a distinct and challenging clinical entity contributing to lower urinary tract symptoms (LUTS). Minimally invasive treatments, such as transperineal laser ablation (TPLA), offer potential advantages in treating this subgroup, but limited data exist regarding their outcomes.
Efficacy and safety of Serenoa repens in benign prostatic disorders: a systematic review of recent clinical evidence.
- Details
This systematic review assessed the potential effectiveness and safety of Serenoa repens (saw palmetto) for benign prostatic disorders, mainly benign prostatic hyperplasia and associated lower urinary tract symptoms.
Quantitative CT biomarkers for predicting clinical outcomes after prostatic artery embolization: Results of the prospective pilot EMBOPERF study.
- Details
The purpose of this study was to prospectively evaluate whether quantitative variables obtained using computed tomography (CT) perfusion and dual-energy CT (DECT) can predict 3-month clinical success after prostatic artery embolization (PAE) in patients with benign prostatic hyperplasia (BPH).
Clinical outcomes of benign prostatic hyperplasia surgery in men with detrusor underactivity versus normal contractility: a systematic review and meta-analysis.
- Details
Detrusor underactivity (DUA) may coexist in up to one-third of men with benign prostatic hyperplasia (BPH) and is traditionally associated with poorer surgical outcomes, as impaired contractility may limit postoperative voiding recovery.